Rib-X C.E.O. Susan Froshauer, Ph.D., Honored by The Connecticut Women's Hall of Fame
New Haven, Connecticut. October 31, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery, development and commercialization of
novel antibiotics for the treatment of antibiotic resistant infections, today announced
that President and C.E.O., Susan Froshauer, Ph.D., was honored last night by the Connecticut
Women's Hall of Fame at their 15th Annual Gala & Induction Ceremony. As part of this
year's event, a group of 15 women were recognized as members of the "New Century of Women in
Science" along with four high school and college age students for their innovation and
commitment to the advancement of the scientific and engineering fields.
This year's inductees included Nobel Prize Winner Barbara McClintock, Ph.D., world renowned Yale University neuroscientist Patricia Goldman-Rakic, Ph.D., Yale University Sterling Professor of Molecular Biophysics Joan Steitz, Ph.D., and leading cell biologist Jewel Plummer Cobb, Ph.D. Previous inductees include Florence Wald, the founder of hospice care in the U.S., Emeline Roberts Jones, D.D.S., the first female dentist in the U.S., Hellen Keller and Katharine Hepburn.
"I am humbled to be a part of this collective group of women pioneers and to have been recognized by my peers," said Susan Froshauer, Ph.D., President and C.E.O. of Rib-X Pharmaceuticals. "By continuing to shine a light on the amazing contributions of young Connecticut women, The Connecticut Women's Hall of Fame, is ensuring that these women are recognized for their impressive achievements at a local level."
This year's inductees included Nobel Prize Winner Barbara McClintock, Ph.D., world renowned Yale University neuroscientist Patricia Goldman-Rakic, Ph.D., Yale University Sterling Professor of Molecular Biophysics Joan Steitz, Ph.D., and leading cell biologist Jewel Plummer Cobb, Ph.D. Previous inductees include Florence Wald, the founder of hospice care in the U.S., Emeline Roberts Jones, D.D.S., the first female dentist in the U.S., Hellen Keller and Katharine Hepburn.
"I am humbled to be a part of this collective group of women pioneers and to have been recognized by my peers," said Susan Froshauer, Ph.D., President and C.E.O. of Rib-X Pharmaceuticals. "By continuing to shine a light on the amazing contributions of young Connecticut women, The Connecticut Women's Hall of Fame, is ensuring that these women are recognized for their impressive achievements at a local level."
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development
company focused on the structure based design of new classes of antibiotics. The Company's
underlying drug discovery engine capitalizes on its proprietary high-resolution crystal
structure of the ribosome, which performs an essential role in protein synthesis. Many known,
commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The
Company's integrated research strategy, which combines state-of-the-art, proprietary computational
analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it
to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms.
Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can
be used for the treatment of either community or hospital acquired infections. Radezolid (RX-1741),
an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections.
The
Rχ-04
discovery program is developing novel classes of antibiotics active against multi drug
resistant Gram-negative bacteria and the
Rχ-02
discovery program is focused on developing an IV/oral
macrolide active against methicillin resistant
S. aureus,
multidrug resistant
Streptococcus pneumoniae
and
S. pyogenes.
Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active
against a broad spectrum of bacteria, including quinolone resistant Gram-positive bacteria and MRSA.
Both radezolid and delafloxacin are currently in Phase 2 clinical trials.
About The Connecticut Women's Hall of Fame
The Connecticut Women's Hall of Fame is an educational outreach organization whose mission is to
honor publicly the achievement of Connecticut women, preserve their stories, educate the public
and inspire the continued achievements of women and girls. Founded in 1994 in Hartford, Connecticut,
the Hall fills the void that traditional curricula still fail to address and today stands as
the state's premier source for women's history with over 85 Inductees. These women's lives
and accomplishments are celebrated and documented through a wide spectrum of innovative
statewide programs offered free of charge to Connecticut citizens. The CWHF Website, which is
an educational tool receiving more than 100,000 individual visits each year, attracts international,
national and local researchers, teachers and students. For more information please visit
www.cwhf.org.
| Media/Investor Contact Information |
|---|
|
Gina Nugent
The Yates Network 617.460.3579 gina@theyatesnetwork.com |